95 related articles for article (PubMed ID: 18718212)
1. Markers of D(2) and D(3) receptor activity in vivo: PET scan and prolactin.
Thomasson-Perret N; Pénélaud PF; Théron D; Gouttefangeas S; Mocaër E
Therapie; 2008; 63(3):237-42. PubMed ID: 18718212
[TBL] [Abstract][Full Text] [Related]
2. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
[TBL] [Abstract][Full Text] [Related]
3. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
Yamada Y; Ohno Y; Nakashima Y; Fukuda M; Takayanagi R; Sato H; Tsuchiya F; Sawada Y; Iga T
Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
[TBL] [Abstract][Full Text] [Related]
4. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
[TBL] [Abstract][Full Text] [Related]
5. [Receptor occupancy and antipsychotic drug action measured by PET and SPECT].
Okubo Y; Suhara T
Seishin Shinkeigaku Zasshi; 2001; 103(4):329-40. PubMed ID: 11392846
[TBL] [Abstract][Full Text] [Related]
6. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature.
Stone JM; Davis JM; Leucht S; Pilowsky LS
Schizophr Bull; 2009 Jul; 35(4):789-97. PubMed ID: 18303092
[TBL] [Abstract][Full Text] [Related]
7. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
8. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats.
Kapur S; Langlois X; Vinken P; Megens AA; De Coster R; Andrews JS
J Pharmacol Exp Ther; 2002 Sep; 302(3):1129-34. PubMed ID: 12183672
[TBL] [Abstract][Full Text] [Related]
9. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable.
Medori R; Mannaert E; Gründer G
Eur Neuropsychopharmacol; 2006 May; 16(4):233-40. PubMed ID: 16326078
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of antipsychotic drug-induced movement disorders.
Casey DE
J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization.
Micheli F; Holmes I; Arista L; Bonanomi G; Braggio S; Cardullo F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Terreni S; Heidbreder C; Savoia C; Griffante C; Worby A
Bioorg Med Chem Lett; 2009 Aug; 19(15):4011-3. PubMed ID: 19553113
[TBL] [Abstract][Full Text] [Related]
12. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY; Huang M
Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
[TBL] [Abstract][Full Text] [Related]
13. [The dopamin D3 receptor--the gray eminence of pharmacotherapy?].
Sumegi A; Varga E
Neuropsychopharmacol Hung; 2010 Sep; 12(3):405-11. PubMed ID: 20962360
[TBL] [Abstract][Full Text] [Related]
14. Side effects profile in humans of (11)C-(+)-PHNO, a dopamine D(2/3) agonist ligand for PET.
Mizrahi R; Houle S; Vitcu I; Ng A; Wilson AA
J Nucl Med; 2010 Mar; 51(3):496-7. PubMed ID: 20150251
[No Abstract] [Full Text] [Related]
15. Striatal dopamine D2/D3 receptor availability in male smokers.
Yang YK; Yao WJ; McEvoy JP; Chu CL; Lee IH; Chen PS; Yeh TL; Chiu NT
Psychiatry Res; 2006 Jan; 146(1):87-90. PubMed ID: 16343861
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies.
Bennacef I; Salinas CA; Bonasera TA; Gunn RN; Audrain H; Jakobsen S; Nabulsi N; Weinzimmer D; Carson RE; Huang Y; Holmes I; Micheli F; Heidbreder C; Gentile G; Rossi T; Laruelle M
Bioorg Med Chem Lett; 2009 Sep; 19(17):5056-9. PubMed ID: 19635669
[TBL] [Abstract][Full Text] [Related]
17. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
18. Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation.
Maggio R; Novi F; Rossi M; Corsini GU; Millan MJ
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S139-44. PubMed ID: 18585083
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
20. The correlation between striatal dopamine D2/D3 receptor availability and verbal intelligence quotient in healthy volunteers.
Guo JF; Kuang Yang Y; Tsing Chiu N; Lieh Yeh T; See Chen P; Lee IH; Lin Chu C
Psychol Med; 2006 Apr; 36(4):547-54. PubMed ID: 16359604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]